Series Introduction: Replication-selective microbiological agents: fighting cancer with targeted germ warfare
Authors: David H. Kirn
Journal: Journal of Clinical Investigation (2000)

This Perspective series on cancer biotherapy will review the emerging field of tumor-targeted microorganisms. The clinical efficacy of any cancer treatment depends on both its antitumoral potency and the therapeutic index between cancerous cells and normal cells. Most current nonsurgical therapies for solid tumors fail on one or both scores, and it is unlikely that changes in dose or frequency, or even the combination of standard cytotoxic chemo- or radiotherapies, will satisfy both of these standards. Novel therapeutic approaches are required that offer greater potency and selectivity and that act by mechanisms not subject to cross-resistance when combined with standard therapies. Tumor-targeted microorganisms have the potential to fit all of these criteria. Their ability to replicate in tumor tissue allows for a massive amplification of the input “dose” (e.g., 1,000- to 10,000-fold increases) at the tumor site, while their lack of replication in normal tissues allows for efficient clearance and reduced toxicity.

Infectious organisms such as viruses and bacteria have evolved to replicate and spread in human tissues. In many cases, infection leads to tissue destruction, either through direct or immune-mediated effects (Table ​(Table1).1). Not long after the discovery and characterization of bacteria and viruses, investigators conceived that the cell-killing potential of these agents could be used to destroy cancer cells (1). Over the last century, diverse viruses — adenovirus, Bunyamwara, coxsackie, dengue, feline panleukemia, Ilheus, mumps, Newcastle disease, vaccinia, and West Nile (2–4) — were injected into cancer patients by various routes, and bacterial agents have also been used as cancer therapies. Since the original description by Coley of tumor regressions following bacterial injection (5, 6), a variety of bacterial agents have been used as immune adjuvants, including Bacillus Calmette-Guerin (BCG) which eventually became the standard of care for superficial recurrent bladder carcinoma (7).



Table 1

Replication-selective microbiological agents in clinical trials for cancer patients



These studies illustrated both the promise of cancer biotherapy and the hurdles to be overcome. Both bacteria and viruses replicated within tumors and spread to distant tumor sites and many patients benefited from some degree of tumor necrosis, but patients were generally not properly evaluated by objective tumor response criteria. Many of the tumor responses appear to have been transient or incomplete, and while some of these agents were well-tolerated, toxicity occurred in some trials.

Since the time of these pioneering but poorly controlled clinical trials, revolutionary advances in molecular biology and genetics established mechanisms for carcinogenesis as well as for microbial replication and pathogenicity. These advances also allowed novel agents to be engineered to improve their safety and/or their antitumoral potency. In recent years, genetically engineered microorganisms in development have included herpesviruses (8) (R. Martuza, in this Perspective series), adenoviruses (9) (C. Heise and D. Kirn, this series), vaccinia (10) (M. Mastrangelo et al., this series) and Salmonella species (11) (M. Sznol et al., this series). In addition, the inherent tumor-selectivity of agents such as reovirus has been characterized at the genetic level (K. Norman and P. Lee, this series). Each of these agents has shown tumor selectivity in vitro and in vivo, and work in murine tumor models has established the efficacy of these treatments.

Until recently, detailed biological data from clinical trials was lacking, but now, as described by C. Heise and D. Kirn (this series), reports from ongoing clinical trials show that the engineered adenoviral mutant dl1520 (ONYX-015, now known as CI-1042, Park-Davis Pharmaceuticals, Inc., division of Warner Lambert, Inc. Ann Arbor, Michigan, USA) replicates and induces necrosis selectively in human tumors (12). Neutralizing antibodies to the virus do not demonstrably prevent antitumoral activity following intratumoral injection. The adenovirus can be delivered to tumors through intra-arterial or intravenous administration, as well. These studies also indicate that this novel biotherapy can interact in a potentially synergistic fashion with standard chemotherapeutic agents (13); a phase III randomized trial of cisplatin plus 5-fluorouracil (5-FU) with or without dl1520 is to be initiated in the first half of 2000. Cross-resistance between agents with such radically different mechanisms of action is unlikely, and combinations may be well-tolerated, particularly if the toxicity profiles of each agent are nonoverlapping. For example, dl1520 causes flulike symptoms, whereas 5-FU suppresses hematopoiesis and causes mucositis.